45 Identifying Optimal Candidates for GLP-1RA Therapy in Heart Failure The selection of patients with HF for GLP-1RA therapy requires careful consideration of the HF phenotype, comorbidities and available evidence
Safety Considerations and Provider-Guided Personalization Semaglutide at any dose requires baseline assessment of pancreatic history, thyroid function, kidney function, and gastrointestinal tolerance
This risk may be compounded by the unregulated manufacturing and distribution of peptides in the gray market, where purity and sterility cannot be assured. Long-Term Effects Finally, the long-term effects of many peptides remain poorly understood
Its dark, cobalt blue color indicates high quality, and it dissolves effortlessly in any formulation
Most first timers on the 2 mg starting dose have a quiet, uneventful first month, which is exactly the point of starting low
Trial data indicates 20 to 30% of weight lost on GLP-1 medications can come from muscle if protein intake and resistance training are neglected